SEC Form 4
Phio Pharmaceuticals Corp. (PHIO) insider trading
In the 12 months to Oct 26, 2026, 3 PHIO insiders reported open-market purchases of $91.3K across 11 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $91.3K
- 11 filings
Who traded PHIO, and when
- Purchase
PHIO daily close from Oct 27, 2025 to Oct 26, 2026, between $0.85 and $2.16, last $0.86. 0 sale and 11 purchase filings by 3 insiders, marked at their filing dates. Robert J. Bitterman, Chairman, Pres. & CEO: bought $44.9K across 7 filings, first filed Nov 19, 2025, last Sep 23, 2026. Ronald Todd Plott, Director: bought $27.5K across 2 filings, first filed Aug 20, 2026, last Sep 30, 2026. Patricia A. Bradford, Director: bought $18.9K across 2 filings, first filed Sep 16, 2026, last Sep 25, 2026.
Largest mark · tap a row for others
Ronald Todd Plott · Director
Purchase $17,100
15,000 shares at $1.14 avg
Filed Aug 20, 2026 · traded Aug 19
Close on filing date $1.21
Robert J. Bitterman · Chairman, Pres. & CEO
Chairman, Pres. & CEO
$44.9K boughtRonald Todd Plott · Director
Director
$27.5K boughtPatricia A. Bradford · Director
Director
$18.9K boughtOpen-market trades
11 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Robert J. Bitterman | Chairman, Pres. & CEO | — | $44.9K | 7 | — | |
| Ronald Todd Plott | Director | — | $27.5K | 2 | — | |
| Patricia A. Bradford | Director | — | $18.9K | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Ronald Todd Plott Director | Purchase | 10,000 | $1.04 | $10.4K | 42,000 | |
traded | Patricia A. Bradford Director | Purchase | 6,500 | $1.01 | $6.6K | 64,151 | |
traded | Robert J. Bitterman Chairman, Pres. & CEO | Purchase | 2,000 | $1.03 | $2.1K | 364,871 | |
traded | Patricia A. Bradford Director | Purchase | 12,000 | $1.03 | $12.4K | 57,651 | |
traded | Ronald Todd Plott Director | Purchase | 15,000 | $1.14 | $17.1K | 15,000 | |
traded | Robert J. Bitterman Chairman, Pres. & CEO | Purchase | 10,000 | $1.06 | $10.6K | 431,421 | |
traded | Robert J. Bitterman Chairman, Pres. & CEO | Purchase | 10,000 | $0.99 | $9.9K | 421,421 | |
traded | Robert J. Bitterman Chairman, Pres. & CEO | Purchase | 5,000 | $1.03 | $5.2K | 291,421 | |
traded | Robert J. Bitterman Chairman, Pres. & CEO | Purchase | 5,000 | $1.02 | $5.1K | 286,421 | |
traded | Robert J. Bitterman Chairman, Pres. & CEO | Purchase | 5,000 | $1.14 | $5.7K | 281,421 | |
traded | Robert J. Bitterman Chairman, Pres. & CEO | Purchase | 5,000 | $1.27 | $6.4K | 276,421 |
GET /stocks/filings/vX/form-4?tickers=PHIO&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"PHIO"
],
"issuer_cik": "0001533040",
"owner_cik": "0001768337",
"accession_number": "0001683168-26-007499",
"form_type": "4",
"filing_date": "2026-09-30",
"period_of_report": "2026-09-28",
"issuer_name": "Phio Pharmaceuticals Corp.",
"issuer_trading_symbol": "PHIO",
"owner_name": "Plott Ronald Todd",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock, $.0001 par value",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-29",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 5000,
"transaction_price_per_share": 1.04,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 42000,
"transaction_value": 5200,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Includes shares of common stock underlying unvested restricted stock units."
}
]
},
{
"tickers": [
"PHIO"
],
"issuer_cik": "0001533040",
"owner_cik": "0001768337",
"accession_number": "0001683168-26-007499",
"form_type": "4",
"filing_date": "2026-09-30",
"period_of_report": "2026-09-28",
"issuer_name": "Phio Pharmaceuticals Corp.",
"issuer_trading_symbol": "PHIO",
"owner_name": "Plott Ronald Todd",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock, $.0001 par value",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-28",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 5000,
"transaction_price_per_share": 1.03,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 37000,
"transaction_value": 5150,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Includes shares of common stock underlying unvested restricted stock units."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 11 records
- Tax withholding2 records
- Grants and awards9 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Phio Pharmaceuticals Corp.'s CEO sold stock?
No. Robert J. Bitterman (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is PHIO’s insider data?
These are PHIO Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track PHIO insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for PHIO every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.